Sam Riahi

Prof. Dr. Sam Riahi

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2012 in Scandinavian Cardiovascular Journal
Verified
Journal Article
Closed access
TRThomas Andersen Rix
Thomas Andersen Rix
SRSam Riahi
Sam Riahi
KOKim Overvad
Kim Overvad
SLSøren Lundbye-Christensen
Søren Lundbye-Christensen
ESErik Berg Schmidt
Erik Berg Schmidt
AJAlbert Marni Joensen
Albert Marni Joensen
To assess the validity of the diagnoses of atrial fibrillation (AF) and atrial flutter (AFL) for men and women recorded in the Danish National Patient Registry, and to assess the relative distribution of AF and AFL. Review of medical records for incident cases of AF and/or AFL in the Diet, Cancer, and Health cohort study. Participants were enrolled in 1993-97 with 13.6 years of follow-up until 30 December, 2009. The positive predictive value of the combined diagnosis of AF and/or AFL was 92.6% (95% CI 88.8%; 95.2%) with no significant difference between sexes (men 93.7% (133/142), women 90.8% (129/142)). The proportion of AFL either alone or in combination with AF was significantly higher in men than in women (13.5% (18/133) vs. 5.4% (7/129), p =0.03). The positive predictive value of the specified diagnosis of AFL was 57.5% for men (46/80) and 29.6% for women (8/27). This study shows that the validity of the diagnosis of AF and/or AFL is high and may be used for registry-based studies. A specified diagnosis of AFL was rarely used and was not reliable to distinguish between cases of AF and AFL.

1 May 2017 in JACC
Verified
Journal Article
Closed access
VRVivek Y. Reddy
Vivek Y. Reddy
MMMarc A. Miller
Marc A. Miller
PNPetr Neuzil
Petr Neuzil
PSPeter Søgaard
Peter Søgaard
CBChristian Butter
Christian Butter
SRSam Riahi
Sam Riahi

31 January 2014 in European Heart Journal
Verified
Journal Article
Open access
PDF file
Elena ArbeloElena Arbelo
Elena Arbelo
JBJosep Brugada
Josep Brugada
GHGerhard Hindricks
Gerhard Hindricks
Aldo Pietro MaggioniAldo Pietro Maggioni
Aldo Pietro Maggioni
LTLuigi Tavazzi
Luigi Tavazzi
AIAtrial Fibrillation Ablation Pilot Study Investigators
Atrial Fibrillation Ablation Pilot Study Investigators
The Atrial Fibrillation Ablation Pilot Study is a prospective registry designed to describe the clinical epidemiology of patients undergoing an atrial fibrillation (AFib) ablation, and the diagnostic/therapeutic processes applied across Europe. The aims of the 1-year follow-up were to analyse how centres assess in routine clinical practice the success of the procedure and to evaluate the success rate and long-term safety/complications. Seventy-two centres in 10 European countries were asked to enrol 20 consecutive patients undergoing a first AFib ablation procedure. A web-based case report form captured information on pre-procedural, procedural, and 1-year follow-up data. Between October 2010 and May 2011, 1410 patients were included and 1391 underwent an AFib ablation (98.7%). A total of 1300 patients (93.5%) completed a follow-up control 367 ± 42 days after the procedure. Arrhythmia documentation was done by an electrocardiogram in 76%, Holter-monitoring in 52%, transtelephonic monitoring in 8%, and/or implanted systems in 4.5%. Over 50% became asymptomatic. Twenty-one per cent were re-admitted due to post-ablation arrhythmias. Success without antiarrhythmic drugs was achieved in 40.7% of patients (43.7% in paroxysmal AF; 30.2% in persistent AF; 36.7% in long-lasting persistent AF). A second ablation was required in 18% of the cases and 43.4% were under antiarrhythmic treatment. Thirty-three patients (2.5%) suffered an adverse event, 272 (21%) experienced a left atrial tachycardia, and 4 patients died (1 haemorrhagic stroke, 1 ventricular fibrillation in a patient with ischaemic heart disease, 1 cancer, and 1 of unknown cause). The AFib Ablation Pilot Study provided crucial information on the epidemiology, management, and outcomes of catheter ablation of AFib in a real-world setting. The methods used to assess the success of the procedure appeared at least suboptimal. Even in this context, the 12-month success rate appears to be somewhat lower to the one reported clinical trials.

24 May 2012 in EP Europace
Verified
Journal Article
Open access
PDF file
Elena ArbeloElena Arbelo
Elena Arbelo
JBJosep Brugada
Josep Brugada
GHGerhard Hindricks
Gerhard Hindricks
Aldo Pietro MaggioniAldo Pietro Maggioni
Aldo Pietro Maggioni
LTLuigi Tavazzi
Luigi Tavazzi
OIon behalf of the Atrial Fibrillation Ablation Pilot Study Investigators
on behalf of the Atrial Fibrillation Ablation Pilot Study Investigators
The Atrial Fibrillation Ablation Pilot Study is a prospective, multinational registry conducted by the European Heart Rhythm Association of the European Society of Cardiology that has been designed to describe the clinical epidemiology of patients undergoing an atrial fibrillation (AFib) ablation procedure, and the diagnostic/therapeutic processes applied in these patients across Europe. We present the results of the short-term (in-hospital) analysis. A total of 72 centres in 10 European countries were asked to enrol 20 consecutive patients scheduled for a first AFib ablation procedure. Between October 2010 and May 2011, 1410 patients were included, of which 1391 underwent an AFib ablation (98.7%). The median age was 60 years [inter-quartile range (IQR) 52–66], and 28% were females. Two-thirds presented paroxysmal AFib and 38% lone AFib. Symptoms were present in 86%. The indications for ablation were mostly symptomatic AFib, but in over a third of patients there was also a desire for a drug-free lifestyle and the maintenance of sinus rhythm. Pulmonary vein isolation was attempted in 98.4% of patients, the roof line in 21.3% and the mitral isthmus line in 12.8%. Complex-fractionated atrial electrograms were targeted in 17.9% and the ganglionated plexi in 3.3%. Complications occurred in 7.7%, of which 1.7% was major (i.e. cardiac perforation, myocardial infraction, endocarditis, cardiac arrest, stroke, hemothorax, pneumothorax, and sepsis). The median duration of hospitalization was 3 days (IQR 2–4). At discharge, 91.4% of patients were in sinus rhythm, 88.3% of patients were given vitamin K antagonists, and 67% antiarrhythmic medication. There was one death after the ablation procedure. The AFib Ablation Pilot Study provides crucial information on AF ablation in clinical practice across Europe. These data are relevant for further improvement of the management strategies of patients suffering from atrial fibrillation.

20 January 2015 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
TZTomas Zaremba
Tomas Zaremba
AJAnnette Ross Jakobsen
Annette Ross Jakobsen
MSMette Søgaard
Mette Søgaard
ATAnna Margrethe Thøgersen
Anna Margrethe Thøgersen
MJMartin Johansen
Martin Johansen
SRSam Riahi
Sam Riahi

22 August 2019 in European Heart Journal
Verified
Journal Article
Closed access
BTBhupendar Tayal
Bhupendar Tayal
PFPatricia Zerlang Fruelund
Patricia Zerlang Fruelund
PSPeter Sogaard
Peter Sogaard
SRSam Riahi
Sam Riahi
CPChristoffer Polcwiartek
Christoffer Polcwiartek
KKKristian Hay Kragholm
Kristian Hay Kragholm
Aims: The objective of the current study is to investigate the risk of heart failure (HF) after implantation of a pacemaker (PM) with a right ventricular pacing (RVP) lead in comparison to a matched cohort without a PM and factors associated with this risk. Methods and results: All patients without a known history of HF who had a PM implanted with an RVP lead between 2000 and 2014 (n = 27 704) were identified using Danish nationwide registries. An age- and gender-matched control cohort (matched 1:5, n = 138 520) without PM and HF was identified to compare the risk. Outcome was the cumulative incidence of HF including fatal HF within the first 2 years of PM implantation, with all-cause mortality and myocardial infarction (MI) as competing risks. Due to violation of proportional hazards, the follow-up period was divided into three time-intervals: 180 days–2 years. The cumulative incidence of HF including fatal HF was observed in 2937 (10.6%) PM patients. Risks for the three time-intervals were 180 days (HR 1.11, 95% CI 1.04–1.17). Among patients with a PM device, factors associated with increased risk of HF were male sex (HR 1.33, 95% CI 1.24–1.43), presence of chronic kidney disease (CKD) (HR 1.64, 95% CI 1.29–2.09), and prior MI (1.77, 95% 1.50–2.09). Conclusions: Pacemaker with an RVP lead is strongly associated with risk of HF specifically within the first 6 months. Patients with antecedent history of MI and CKD had substantially increased risk.